Nanoco to Present at Upcoming Industry Conferences
18.2.2025 12:00:00 CET | Business Wire | Press release
Nanoco Group PLC (LSE: NANO), a world leader in the development and manufacture of cadmium-free quantum dots and other advanced nanomaterials, is ramping up its commercial engagement as it transitions to scaled production. Over the coming months the company will be attending several key industry events to showcase its technology, connect with its customers and development partners, and to accelerate adoption of its solutions.
In March, Nanoco Founder and CTO Dr. Nigel Pickett will speak at the Society for Information Display (SID) UK Chapter meeting in London. His presentation, “Molecular Seeding Technology for Display Applications and Beyond,” will explain how Nanoco’s technology can enhance micro-LED and other displays, making them more efficient and cost-effective for mass production. As the industry moves toward brighter, more energy-efficient screens, Nanoco is working with partners to bring its technology into commercial products.
Later that month Nanoco will attend and sponsor Image Sensors Europe, a major industry gathering of over 250 vision technology professionals. The team will engage with potential customers and partners, highlighting how Nanoco’s quantum dot-based imaging solutions are unlocking new possibilities across several industries.
In April, Nanoco will be presenting its latest results on Image Sensors at SPIE Defense + Commercial Sensing conference in Orlando, Florida. The presentation, “Molecular Seeding Technology: Enabling Sensing Applications of the Future,” will highlight how Nanoco’s technology enables the production of Quantum Dots at scale making high-performance infrared image sensors more affordable and available. These sensors are in growing demand and Nanoco is positioning itself as a key player in that industry.
Nigel Pickett, Ph.D., the founder and CTO of Nanoco, said:
"Molecular seeding technology is our foundational IP for high volume quantum dot production. It allows us to manufacture high-quality materials efficiently, meeting the strict demands of the electronics industry. We believe it is the only feasible method to manufacture Quantum Dots at scale. This technology has already played a pivotal role in advancing display technologies, and we are now seeing the same potential in quantum dot enabled sensing applications where Nanoco has the largest product portfolio.
Dmitry Shashkov, Ph.D., CEO of Nanoco, said:
"We are excited to present our latest achievements to the industry and take the next steps to align the business with commercial execution. These industry events are not just about presenting technology—they are about building relationships with partners and customers who will be instrumental in bringing QD Image Sensors into mass adoption. We at Nanoco see the next 1-2 years as a major inflection point for the industry, as low-cost, wafer-scale production processes will bring QD Image Sensors to a wide variety of applications, including consumer, automotive, industrial and defense sectors."
About Nanoco Group plc
Nanoco (LSE: NANO) is a nanomaterial production and licensing group, specialising in the production of its patented cadmium-free quantum dots (CFQD®) and other nanomaterials for use in the electronics industry. Founded in 2001 and headquartered in Runcorn, UK, Nanoco continues to build a world-class, patent-protected IP portfolio alongside its existing scaled-up production facilities for commercial orders.
For further information, please visit: www.nanocotechnologies.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20250218331567/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Owkin Creates New Spin out Waiv, Formerly Owkin Dx, With $33M Financing12.3.2026 14:30:00 CET | Press release
Investment lead by OTB Ventures and Alpha Intelligence CapitalWaiv develops AI-powered precision testing to better identify and stratify patients in the clinic and in clinical trials, transforming patient careWaiv extends Owkin’s strategy of real-world validation for its AI Owkin, the AI company on a mission to solve the complexity of biology, today announced the spin out of Waiv, formerly known as Owkin Dx. The move follows significant investor interest and positions Waiv to bring AI-powered precision testing for better identification of patients in the clinic and in clinical trials, to transform patient care. This follows on from the successful launch of Bioptimus, an Owkin incubated company, in February 2024. Waiv translates AI innovation into real-world clinical impact, developing tests that predict biomarkers and patient outcomes, including RlapsRisk BC for prognostic risk profiling. With multiple tests already in use in clinical settings, its deployment platform Destra, and colla
RQM+ Launches SMART Solutions Life Cycle Partnership Model12.3.2026 14:30:00 CET | Press release
Helps MedTech Companies Navigate MDR, IVDR, and AI-Enabled Device Development RQM+, a leading MedTech CRO offering regulatory consulting, clinical trial, laboratory, and reimbursement services, today announced the launch of SMART Solutions, a life cycle partnership model designed to help medical device and diagnostics companies manage growing regulatory and development complexity. SMART Solutions introduces a strategy-led operating framework that unifies regulatory, quality, clinical, reimbursement, and laboratory expertise to support MedTech companies across the entire product life cycle to help reduce risk from early development through post-market. “MedTech companies are navigating unprecedented complexity as regulatory expectations evolve, product innovation accelerates, and post-market expectations are expanding,” said John Potthoff, Ph.D., chief executive officer of RQM+. “SMART Solutions moves beyond traditional consulting by providing an integrated life cycle partnership that h
Cryptio Raises $45m Series B as Digital Assets Move Into Regulated Financial Markets12.3.2026 14:06:00 CET | Press release
The system of record for tokenized finance – ERP infrastructure for institutions operating in digital assets Cryptio, a leader in financial data transformation and enterprise resource planning (ERP) applications for regulated digital assets, announced today a $45 million Series B funding round co-led by BlackFin Capital Partners and Sentinel Global, with participation from 1kx, Alven, BlueYard Capital and Ledger Cathay Capital. Banks, exchanges, asset managers, including Société Générale’s SG Forge, Circle, Gemini, and Securitize rely on Cryptio to ensure financial integrity across their digital assets businesses. Existing ERP systems fall short for digital assets Traditional ERP and accounting systems were not designed for blockchain-native assets, real-time reporting, or modern custody frameworks. As regulated financial institutions expand into stablecoins, tokenized securities and other on-chain instruments, these limitations create material operational and reporting challenges. Cry
HyperLight Introduces 145 GHz Reference Modulators to Enable 448Gbps per Lane Datacom and 260GBaud Telecom Development12.3.2026 14:03:00 CET | Press release
HyperLight Corporation, creator of the TFLN Chiplet™ platform, today announced the release of its 145 GHz Packaged Intensity Modulator (IM), expanding the company‘s high-speed modulator portfolio. The new device is designed for ultra-wide modulation bandwidth, high signal fidelity, and stable operation control, enabling 448 Gbps per lane intensity-modulated-direct-detection (IMDD), 260 GBaud coherent links, and broadband RF photonics systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260312319685/en/ Fig. 1: HyperLight’s 145 GHz intensity modulator for 448Gbps per lane IMDD and 260GBaud coherent applications, with operational electro-optical bandwidth >145GHz, stable bias control, 0.8 mm-connector; available in O-, C-, and L-bands. As symbol rates and analog bandwidth requirements continue to rise across data center interconnects, AI-driven photonics infrastructure, and laboratory test environments, system architects in
Enodia Therapeutics Strengthens Sec61 Portfolio Through Acquisition of Preclinical Assets from Kezar Life Sciences12.3.2026 14:00:00 CET | Press release
Transaction deepens insights into Sec61 selectivity for targeted protein degradation, supporting accelerated development of Enodia’s novel small-molecule inhibitors Enodia Therapeutics, a biotechnology company developing novel small-molecule therapies for targeted protein degradation at the point of synthesis, and Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that Enodia has acquired Kezar’s assets from its Sec61-based discovery and development program. The acquisition enables Enodia to advance its understanding of Sec61 selectivity mechanisms, expanding biological and translational insights for faster progression toward key clinical milestones. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260312627573/en/ Under the terms of the purchase agreement between Enodia and Kezar, Kezar w
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom